Neuphoria Therapeutics
NEUP
3 hedge funds and large institutions have $1.46M invested in Neuphoria Therapeutics in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
5% less capital invested
Capital invested by funds: $1.54M → $1.46M (-$78K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$529 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WP
1
Woodline Partners
San Francisco,
California
| $884K | – | – | – |
|
|
BI
2
BVF Inc
San Francisco,
California
| $578K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $1K | +$529 | +6 | +120% |
|
NEUP Hedge Fund Activity: Q3 2022 in Review
3 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q3 2022, worth a combined $1.46M — down 5.1% from $1.54M a quarter earlier.
Fund positioning in NEUP was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $529.
- 3 institutional investors held Neuphoria Therapeutics (NEUP) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $1.46M of Neuphoria Therapeutics stock for Q3 2022, down 5.1% quarter-over-quarter.
- 0 funds opened new Neuphoria Therapeutics positions in Q3 2022 and 0 closed out.
- The largest Neuphoria Therapeutics buyer in Q3 2022 was UBS Group, an estimated $529 added.
Based on aggregated 13F filings for Q3 2022.